Medigen Vaccine Biologics Corporation
Research Medigen Vaccine Biologics Corporation (6547.TWO) on Bullrun: market cap TWD 17.33B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6547.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 17.33B
- Financial periodQ2 2026
- RevenueTWD 115.05M
- Net incomeTWD 22.35M
- Free cash flow-TWD 123.92M
- Gross margin81.5%
Valuation Snapshot
latest market cap is TWD 17.33B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 17.33B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Medigen Vaccine Biologics Corporation
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses.
ETFs that hold Medigen Vaccine Biologics Corporation
US-listed ETFs
Medigen Vaccine Biologics Corporation is held by 9 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | <0.01% | 0.06% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.02% | 0.65% |
| State Street SPDR S&P Emerging Asia Pacific ETF (GMF) | 0.01% | 0.49% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medigen Vaccine Biologics Corporation's market cap?
Medigen Vaccine Biologics Corporation's market capitalization is TWD 17.33B.
What does Medigen Vaccine Biologics Corporation do?
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses.